Press Release Summary = Cambridge Theranostics Ltd (CTL), a biotech spin-out company from Cambridge University, announced today a major deal that will allow CTL to commercialize a novel pharmaceutical product that should provide substantial benefits and health improvements in patients with coronary heart disease. CTL intends to obtain rapid regulatory approval for this pharmaceutical product with a view to launching it as soon as possible.
Press Release Body = Cambridge Theranostics Ltd (CTL), a biotech spin-out company from Cambridge University, announced today a major deal that will allow CTL to commercialize a novel pharmaceutical product that should provide substantial benefits and health improvements in patients with coronary heart disease. CTL intends to obtain rapid regulatory approval for this pharmaceutical product with a view to launching it as soon as possible.
In the deal, signed in 2006, CTL licensed from Nestlé the rights to develop and market pharmaceutical products based on an active ingredient that is a patented formulation developed by the Nestlé Research Centre in Switzerland.
Commenting on the deal, Dr. Gunter Schmidt, CEO said "This deal represents a significant milestone in the 4 year history of CTL. It provides a solid basis to launch our first therapeutic product."Dr.
Ivan Petyaev, Founder CSO said "Having identified one of the key factors of atherosclerosis, we were delighted to partner with Nestlé to develop CT003. This substance is a powerful inhibitor of AtheroAbzymesT and exhibits an excellent safety profile."Nestlé licenses Novel Heart Disease product to Cambridge Theranostics
About Cambridge Theranostics Cambridge Theranostics Ltd. was founded in 2002 and is privately owned. CTL has identified a new causative factor of lipid oxidation, which is a critical step in the development of atherosclerosis, angina, coronary heart disease and stroke, but which has hitherto not been targeted successfully for therapeutic intervention. The newly discovered AtheroAbzymesT are a class of antibody that directly oxidise LDL leading to the initiation or exacerbation of atherosclerotic plaque formation. The new product is a potent inhibitor of AtheroAbzymeT and has demonstrated substantial benefits and health improvements in patients with coronary heart disease. CTL has also developed an AtheroAbzymeT diagnostic test that can be used to identify patients with active atherogenesis even with asymptomatic ischemia. These tests can also be used to select and monitor treatment of patients, with the AtheroAbzymeT inhibitor licensed from Nestlé.
Web Site = http://www.cambridgetheranostics.co.uk/Press_Releases.html
Contact Details = Dr Gunter Schmidt, CEO Tel: +44 (0)7711704816 ghschmidt@cambridgetheranostics.co.uk
2022
